BMY's 4.3% Dividend Yield Hangs on Eliquis Margin Defense in 2026

What happened

Bristol Myers Squibb's dividend, yielding 4.3%, is currently covered by earnings, but the company faces a daunting patent cliff that threatens sustainability. The 2026 bridge year depends on Eliquis delivering +10-15% growth while holding gross margins at 69-70%, as policy resets from the IRA and a Medicaid free-supply agreement take effect. Meanwhile, Revlimid erosion accelerates on January 31, 2026, when generic volume caps expire. Management's guidance for $46-47.5B revenue and $6.05-6.35 EPS assumes this delicate balance holds, but the margin of safety is thin. Investors should wait for Q1-Q2 2026 evidence before concluding the dividend is secure.

Implication

The 4.3% yield is attractive only if gross margins stay above 69% and Eliquis tracks its guide. If margins slip, the dividend may be cut. A WAIT rating with re-assessment in 3-6 months allows investors to avoid a potential de-rating while capturing value if the bridge holds. Target entry at $55, trim above $70.

Thesis delta

The market narrative has shifted from 'dividend safe today' to 'dividend dependent on Eliquis margin defense in 2026.' The DeepValue report confirms the bridge year is policy-fragile, making the dividend less secure than headlines suggest. The 2026 guidance must be validated by observable gross margin prints; until then, the dividend is at risk of a cut if earnings erode.